Intellia Therapeutics(NTLA) - 2024 Q2 - Quarterly Results

Exhibit 99.1 E, LELEBELLI III PRESS RELEASE #11010101011111111 Intellia Therapeutics Announces Second Quarter 2024 Financial Results and Highlights Recent Company Progress - Phase 2 study of NTLA-2002 for hereditary angioedema (HAE) met its primary and all secondary endpoints; plan to present detailed results at an upcoming medical meeting in the fourth quarter - Selected the 50 mg dose of NTLA-2002 for the pivotal Phase 3 trial on track to begin in 2H 2024 - Rapid enrollment continues in the Phase 3 MAGNIT ...